UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(mark one)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 For Quarterly Period Ended June
30, 2000
or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 For Transition Period from
__________ to __________
Commission File No. 0-14710
XOMA Ltd.
(Exact Name of Registrant as specified in its charter)
Bermuda 52-2154066
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2910 Seventh Street, Berkeley, CA 94710
(Address of principal executive offices) (Zip Code)
(510) 644-1170
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Common shares US$.0005 par value 65,450,471
- - - -------------------------------------- --------------------------------
Class Outstanding at June 30, 2000
XOMA Ltd.
TABLE OF CONTENTS
Page
PART I FINANCIAL INFORMATION
Item 1 Consolidated Financial Statements
Condensed Consolidated Balance Sheets as of
June 30, 2000 and December 31, 1999......................1
Condensed Consolidated Statements of Operations
for the Three and Six Months Ended June 30, 2000
and 1999.................................................2
Condensed Consolidated Statements of Cash Flows for
the Six Months Ended June 30, 2000 and 1999 .............3
Notes to Condensed Consolidated Financial Statements ....4
Item 2 Management's Discussion and Analysis of Financial
Condition and Results of Operations .....................7
PART II OTHER INFORMATION
Items 1 through 3 and 5 are either inapplicable or
nonexistent and therefore are omitted from this
report
Item 4 Submission of Matters to a Vote of Security Holders......10
Item 6 Exhibits and Reports on Form 8-K.........................10
Signatures....................................................................11
XOMA Ltd.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
June 30, 2000 December 31, 1999
----------------- -----------------
(Unaudited) (Note 1)
Assets:
Cash and cash equivalents $ 42,333 $ 18,539
Short-term investments 713 --
Related party receivable 189 219
Other receivables 3,724 658
Prepaid expenses and other 46 679
------------- ------------
Total current assets 47,005 20,095
Property and equipment, net 3,400 3,651
Assets held for sale 4,442 4,442
Deposits and other 169 124
------------- ------------
$ 55,016 $ 28,312
============= ============
Liabilities and Shareholders' Equity:
Accounts payable $ 2,789 $ 3,915
Accrued liabilities 5,298 6,519
Deferred revenue - current 3,333 --
------------- ------------
Total current liabilities 11,420 10,434
Deferred revenue-long term 5,277 --
Convertible subordinated notes 33,647 34,724
------------- ------------
Total liabilities 50,344 45,158
Shareholders' equity (net capital deficiency) 4,672 (16,846)
------------- ------------
$ 55,016 $ 28,312
============= ============
Note 1 - Amounts derived from the Company's amended annual report on Form 10-K
as filed with the SEC.
See accompanying notes to condensed consolidated financial statements.
-1-
XOMA Ltd.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
---------------------------- ---------------------------
2000 1999 2000 1999
------------ ------------ ----------- -----------
Revenues:
Contract Revenue $ 2,272 $ 525 $4,834 $ 528
Other Revenue 111 22 21 39
------------ ------------ ----------- -----------
2,283 547 4,855 567
------------ ------------ ----------- -----------
Operating Costs and Expenses:
Research and development 7,390 11,136 14,584 23,409
General and administrative 1,589 1,631 3,115 3,011
------------ ------------ ----------- -----------
8,979 12,767 17,699 26,420
------------ ------------ ----------- -----------
Loss from operations (6,696) (12,220) (12,844) (25,853)
Other Income (Expense):
Investment and other income 985 260 1,475 629
Interest and other expense (615) (403) (1,241) (797)
------------ ------------ ----------- -----------
Net loss (6,326) (12,363) (12,610) (26,021)
Preference share dividends -- -- -- (55)
------------ ------------ ----------- -----------
Net loss available to common
shareholders $(6,326) $(12,363) $(12,610) $(26,076)
============ ============ =========== ===========
Net loss per common share $(0.10) $(0.24) $(0.20) $(0.52)
Shares used in computing net loss
per common share 65,391 50,835 63,531 50,009
See accompanying notes to condensed consolidated financial statements.
-2-
XOMA Ltd.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
Six Months Ended June 30,
-----------------------------
2000 1999
------------ -----------
Cash Flows From Operating Activities:
Net cash provided by (used in) operating activities $ (7,265) $ (22,358)
------------ -----------
Cash Flows From Investing Activities:
Proceeds from sale of short-term investments 506 20,660
Payments for purchase of short-term investments -- (23,601)
Capital expenditures (395) (578)
------------ -----------
Net cash provided by (used in) investing activities 111 (3,519)
------------ -----------
Cash Flows From Financing Activities:
Proceeds from issuance of common shares, net 33,266 11,620
Proceeds (payments) on convertible notes (2,318) 4,000
Capital lease principal payments -- (212)
------------ -----------
Net cash provided by (used in) financing activities 30,948 15,408
------------ -----------
Net increase (decrease) in cash and cash equivalents 23,794 (10,469)
Cash and cash equivalents at beginning of period 18,539 11,857
------------ -----------
Cash and cash equivalents at end of period $ 42,333 $ 1,388
============ ===========
See accompanying notes to condensed consolidated financial statements.
-3-
XOMA Ltd.
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
1. Basis of Presentation
The interim information contained in this report is unaudited but, in
management's opinion, includes all normal recurring adjustments necessary for a
fair presentation of results for the periods presented. Interim results may not
be indicative of results to be expected for the full year. The consolidated
financial statements should be read in conjunction with the Company's audited
consolidated financial statements for the year ended December 31, 1999 included
in its Annual Report on Form 10-K, as amended. The preparation of financial
statements in conformity with generally accepted accounting principles requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities, if
any, at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ
materially from those estimates.
2. Recent Accounting Pronouncements
In December 1999, the Securities and Exchange Commission (SEC) issued Staff
Accounting Bulletin No. 101 (SAB 101), "Revenue Recognition in Financial
Statements." SAB 101 summarizes certain areas in applying generally accepted
accounting principles to revenue recognition in financial statements. In March
2000, the SEC issued SAB101A to defer for one quarter the effective date of
implementation of SAB101 and in June 2000, the SEC issued SAB101B which further
deferred implementation for two more quarters, with earlier application
encouraged. The Company is currently evaluating the impact of SAB 101 as it
relates to the Company's revenue recognition policy. In June 1998, the Financial
Accounting Standards Board (FASB) issued Statement of Financial Accounting
Standards No. 133 (SFAS 133), "Accounting for Derivative Instruments and Hedging
Activities." XOMA is required to adopt SFAS 133 for the year ending December 31,
2002. Because the Company currently holds no derivative financial instruments
and does not currently engage in hedging activities, adoption of SFAS 133 is
expected to have no material impact on the Company's financial position or
results of operations.
In March 2000, the FASB issued Interpretation No. 44, "Accounting for
Certain Transactions Involving Stock Compensation," which provides guidance on
several implementation issues related to Accounting Principles Board Opinion No.
25 (APB 25). The most significant are clarification of the definition of
employee for purposes of applying APB 25 and the accounting for options that
have been repriced. Under the interpretation, the employer-employee relationship
would be based on case law and Internal Revenue Service
-4-
regulations. The FASB granted an exception to this definition for outside
directors. Under the interpretation, repriced options effectively change the
terms of the plan, which would make it a variable plan subject to compensation
expense. The impact of the interpretation on the Company's position and results
of operations is not expected to be material.
3. Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
June 30, December 31,
2000 1999
------------ ------------
Accrued payroll costs $ 3,023 $ 2,928
Accrued clinical trial costs 1,321 2,957
Other 954 634
------------ -----------
$ 5,298 $ 6,519
============ ===========
4. Private Placement
In February 2000, the company issued 6,145,000 common shares for net
proceeds of $29.0 million. The Company also issued five-year warrants to
purchase a total of up to 250,000 common shares for $5.00 per share to its
placement agents in this transaction. These warrants were exercisable upon
issuance and expire in February 2005.
In June 2000, the Company issued 50,000 common shares to third parties. The
net proceeds of $0.2 million were applied against the Company's convertible
subordinated notes to Genentech, Inc.
5. Comprehensive Loss
Comprehensive loss includes certain changes in equity that are excluded
from net loss. Specifically, unrealized holding gains and losses in available
for sale investments, which were reported separately in shareholders' equity,
are included in accumulated other
-5-
comprehensive income (loss). Comprehensive loss and its components for the
quarters ended June 30, 2000 and 1999 are as follows (in thousands):
Three Months Ended Six Months Ended
June 30, June 30,
---------------------------- --------------------------
2000 1999 2000 1999
----------- ----------- ------------ ----------
Net loss $(6,326) $(12,363) $(12,610) $(26,076)
Unrealized gain (loss) on securities
available-for-sale (41) -- 441 --
----------- ----------- ------------ ----------
Comprehensive loss $(6,367) $(12,363) $(12,169) $(26,076)
=========== =========== ============ ==========
5. Net Loss Per Common Share
Basic and diluted net loss per common share is based on the weighted
average number of common shares outstanding during the period in accordance with
Financial Accounting Standard No. 128. Common share equivalents were not
included because they are antidilutive.
7. FDA Meeting
In an April meeting with members of the U.S Food and Drug Administration
(FDA), representatives from XOMA and its licensee, the Hyland Immuno Division of
Baxter Healthcare Corporation, discussed results from Phase III trail that
tested NEUPREX(R) (rBPI21) in pediatric patients with severe meningococcemia.
Senior representatives of the FDA indicated that the data presented were not
sufficient to support the filing of biologics license application (BLA) at this
time. XOMA and Baxter are therefore examining ways to supply the additional data
necessary to proceed with the filing. Because of this event, the filing of a BLA
will be delayed, but by how long is not known at this time.
8. Subsequent Event
In July 2000, the Company issued 200,000 common shares to third parties.
The net proceeds of $1.3 million were applied against the Company's convertible
subordinated notes to Genentech.
-6-
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Results of Operations:
Revenues in the second quarter of 2000 were $2.3 million as compared to $0.5
million in the second quarter of 1999. For the six months ended June 30, 2000,
revenues were $4.9 million compared with $0.6 million in the 1999 period.
Following recent SEC guidance on revenue recognition, revenues in 2000 include
only a portion of a $10 million upfront payment received in January related to
the licensing of NEUPREX(R). A remaining unrecognized balance of $8.6 million
will be recognized ratably over future periods.
Research and development expenses decreased to $7.4 million in the second
quarter of 2000, compared with $11.1 million in the 1999 period. For the six
months ended June 30, 2000, research and development costs were $14.6 million,
compared with $23.4 million in the same period in 1999. The decrease was due
primarily to lower spending on clinical trials for the NEUPREX(R) and anti-CD11a
products. General and administrative spending was $1.6 million and $3.1 million
for three and six months, respectively, ended June 30, 2000, compared with $1.6
million and $3.0 million, respectively, in the comparable 1999 period.
Investment income was higher for the first two quarters of 2000 compared to the
same period in 1999 due to a higher average investment balance.
Liquidity and Capital Resources:
The Company's cash, cash equivalents and short-term investments totaled $43.0
million as of June 30, 2000, up from $18.5 million at December 31, 1999. Net
cash used in operating activities plus capital expenditures were offset by the
net proceeds from common shares issued in February 2000. Net cash used in
operating activities for the six months ended June 30, 2000 was $7.3 million,
compared with a net usage of $22.4 million in the comparable 1999 period. The
decrease in usage was primarily due to lower amounts paid for clinical trials
and preparation of regulatory filings, and receipt of a $10 million initial
payment from Baxter. The Company has also received $33.3 million of net proceeds
from the issuance of common shares in 2000. The Company's cash, cash equivalents
and short-term investments are expected to continue to decrease while the
Company pursues U.S. Food and Drug Administration licensure except to the extent
the Company secures additional funding.
Operating expenses may increase in future periods as the Company proceeds with
various internal development programs. Cash balances and operating cash flow are
influenced by the timing and level of payments by the Company's licensees and
development partners, as well as by the Company's net income.
-7-
The Company has been able to control its operating cash consumption by carefully
monitoring its costs. As a result, its cash position and resulting investment
income are sufficient to finance the Company's currently anticipated levels of
spending through at least the second quarter of 2002. Strategic arrangements
with Allergan, Inc., Baxter and Genentech, Inc. have reduced Company spending
levels by paying certain product development costs. The Company continues to
evaluate a variety of arrangements that would further strengthen its competitive
position and provide additional funding, but cannot predict when or whether any
such arrangement or additional funding will be secured. Without additional
funding, the Company would have to decrease or eliminate the development of some
of its products.
Quantitative and Qualitative Disclosures About Market Risk:
Interest Rate Risk. The Company's exposure to market rate risk due to changes in
interest rates relates primarily to the Company's investment portfolio. The
Company does not use derivative financial instruments in its investment
portfolio. By policy, the Company places its investments with high quality debt
security issuers, limits the amount of credit exposure to any one issuer, limits
duration by restricting the term and holds investments to maturity except under
rare circumstances. The Company classifies its cash equivalents as fixed rate if
the rate of return on an instrument remains fixed over its term. As of June 30,
2000, all the Company's cash equivalents are classified as fixed rate.
The Company also has a long-term convertible note due to Genentech in 2005.
Interest on this note of LIBOR plus 1% is reset at the end of June and December
each year and is therefore variable.
The table below presents the amounts and related weighted interest rates of the
Company's cash equivalents and long-term convertible note at June 30, 2000:
Fair Value Average
Maturity ($ in millions) Interest Rate
---------- --------------- -------------
Cash equivalents, fixed rate Daily $ 41.4 6.3%
Long-term convertible note, variable rate 2005 33.7 7.1%
Other Market Risk. At June 30, 2000 the Company had a long-term convertible note
outstanding which is convertible into common shares based on the market price of
the Company's common shares at the time of conversion. A 10% decrease in the
market price of the Company's common shares would increase the number of shares
issuable upon conversion of either security by approximately 11%. An increase in
the market price of Company common shares of 10% would decrease the shares
issuable by approximately 9%.
-8-
Forward Looking Statements:
Certain statements contained herein that are not related to historical facts may
constitute "forward looking" information, as that term is defined in the Private
Securities Litigation Reform Act of 1995. Such statements are based on the
Company's current beliefs as to the outcome and timing of future events, and
actual results may differ materially from those projected or implied in the
forward looking statements. Further, certain forward looking statements are
based upon assumptions of future events which may not prove to be accurate. The
forward looking statements involve risks and uncertainties including, but not
limited to, those related to regulatory approvals, product efficacy and
development, the Company's financing needs and opportunities, scale-up and
marketing capabilities, intellectual property protection, competition, stock
price volatility and other risk factors referred to herein and in other of the
Company's Securities and Exchange Commission filings.
-9-
PART II - OTHER INFORMATION
Item 1 Legal Proceedings. None.
Item 2 Changes in Securities. None.
Item 3 Defaults Upon Senior Securities. None.
Item 4 Submission of Matters to a Vote of Security Holders.
On May 31, 2000, the Company held the first portion of
its annual general meeting of shareholders. The
following persons (the only nominees) were elected as
the Company's directors, having received the indicated
votes:
Name Votes Votes
---- For Withheld
----- --------
James G. Andress 53,530,015 636,036
William K. Bowes, Jr. 53.539,767 626,284
John L. Castello 53,540,208 625,843
Arthur Kornberg, M.D. 53,564,792 601,259
Steven C. Mendell 53,523,962 642,089
Patrick J. Scannon, M.D., Ph.D. 53,561,534 604,517
W. Denman Van Ness 53,552,015 614,036
The appointment of Ernst & Young LLP to act as the Company's
independent auditors for the 2000 fiscal year was ratified and
the authorization of the Board to agree to such auditors' fee was
approved, having received 53,284,984 votes for, 258,166 votes
against, 622,901 abstentions and no broker non-votes.
Item 5 Other Information. None.
Item 6 Exhibits and Reports on Form 8-K.
Current Report on Form 8-K dated and filed on April 25, 2000
(File No. 0-14710), Items 5 (Other Events) and 7 (Exhibits).
-10-
XOMA Ltd.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
XOMA LTD.
Date: August 14, 2000 By: /s/ JOHN L. CASTELLO
--------------------
John L. Castello
Chairman of the Board, President and
Chief Executive Officer
Date: August 14, 2000 By: /s/ PETER B. DAVIS
------------------
Peter B. Davis
Vice President, Finance and
Chief Financial Officer
-11-